SCHEMBL26535078

SCHEMBL26535078

COc1cc2c(-c3ccc(NC(=O)Cc4ccc(Cl)c(C(F)(F)F)c4)cc3)ncnc2cc1OCC1CCNCC1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KIT P10721 2/20 0.57
▸ CSF1R P07333 1/20 0.57
▸ RET P07949 1/20 0.57
▸ PDGFRB P09619 1/20 0.57
▸ PDGFRA P16234 1/20 0.57
▸ DDR1 Q08345 1/20 0.57
▸ KDR P35968 11/20 0.50
▸ EPHA2 P29317 4/20 0.48
▸ EGFR P00533 6/20 0.47
▸ CA2 P00918 1/20 0.47
▸ CA9 Q16790 1/20 0.47
▸ FGFR1 P11362 4/20 0.46
▸ FLT1 P17948 4/20 0.46
▸ FLT4 P35916 4/20 0.46
▸ EPHB4 P54760 3/20 0.45
▸ ERBB2 P04626 1/20 0.45
▸ MEN1 O00255 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ HTT P42858 1/20 0.44
▸ KMT2A Q03164 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30394312 0.91 KDR (0.47) KITCSF1RRETPDGFRBPDGFRA
SCHEMBL26100211 0.91 KDR (0.47) KITCSF1RRETPDGFRBPDGFRA
SCHEMBL26102088 0.90 PDGFRB (0.55) KITCSF1RRETPDGFRBPDGFRA
SCHEMBL30891790 0.89 KDR (0.46) KITCSF1RRETPDGFRBPDGFRA
SCHEMBL26536043 0.89 KDR (0.46) KITCSF1RRETPDGFRBPDGFRA
SCHEMBL26102350 0.89 KDR (0.46) KITCSF1RRETPDGFRBPDGFRA
SCHEMBL30394313 0.88 AURKA (0.48) KITCSF1RPDGFRBKDREGFR
SCHEMBL29238236 0.88 KIT (0.47) KITCSF1RRETPDGFRBPDGFRA
SCHEMBL30394321 0.88 KIT (0.47) KITCSF1RRETPDGFRBPDGFRA
SCHEMBL29238237 0.88 AURKA (0.48) KITCSF1RPDGFRBKDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US claimed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP claimed
CN-118201909-A Quinazoline derivative compound and use thereof 株式会社沃若诺伊 2024-06-14 — — CN claimed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO claimed
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF VORONOI INC (KR) 2026-05-21 — — US disclosed
EP-4424675-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF Voronoi Inc. (KR) 2024-09-04 — — EP disclosed
WO-2023075529-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF 보로노이바이오 주식회사 2023-05-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260138959-A1 QUINAZOLINE DERIVATIVE COMPOUND AND USE THEREOF PDGFRA, KIT, PDGFRB KIT 2/4885CSF1R 219/4885RET 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback